在禁食和食条件下对中国健康受试者进行两片奥洛帕塔丁化片的生物等价性研究
Yuyan Lei1, Fang Pei2, Qingqi Wu1
1Department of Pharmacology, Xiangya School of Pharmaceutical Science, Central South University, Changsha, China.
Clinical pharmacology in drug development
|November 18, 2025
概括
这项研究证实,仿制的奥洛帕塔丁化片与参考配方具有生物同等性和同等安全性. 摄入食物稍微延迟了吸收,但没有影响这种抗过敏药物的总体生物等价性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
背景情况:
- 奥洛帕塔丁化是一种选择性H1受体对抗剂,用于过敏.
- 评估仿制药配方可确保治疗等价性和可访问性.
研究的目的:
- 为了评估两个olopatadine化片配方的药理动力学和生物等价性.
- 在健康的中国受试者中比较试验和参考配方的安全性.
主要方法:
- 一个随机的,开放的,单剂量,双向交叉研究,涉及48名健康的中国人.
- 在禁食和食 (高脂肪) 条件下单次服用5毫克剂量.
- 通过LC-MS/MS测量了血中的奥洛帕塔丁度,并分析了药理学参数.
主要成果:
- 在禁食或食条件下,在测试和参考配方之间没有观察到显著的药理动力学差异.
- 对于Cmax,AUC0-t和AUC0-∞比率的90%CI都在0.80-1.25的生物等效范围内.
- 高脂饮食降低了Cmax约40%和AUC10-15%,但没有影响生物等价性.
结论:
- 一般的奥洛帕塔丁化片配方与参考产品具有生物等价性.
- 两种配方均表现出可比的安全性概况,没有报告严重不良事件.
相关概念视频
Bioavailability Study Design: Healthy Subjects Versus Patients
136
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
136
Bioequivalence of Drugs: Drugs with Multiple Indications
143
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
143
Bioequivalence: Overview
1.7K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.7K
Bioequivalence studies: Biowaivers
210
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
210
Bioequivalence Data: Statistical Interpretation
184
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
184
Bioavailability Study Design: Single Versus Multiple Dose Studies
189
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
189


